Product Name

Sitagliptin Phosphate monohydrate

General description

Sitagliptin phosphate is a pyrazine-derived Dipeptidyl-peptidase inhibitor and Hypoglycemic agent.

Synonym

7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4 triazolo[4,3-a]pyrazine phosphate; Sitagliptin phosphate; MK-0431

Purity

≥99.0%(HPLC)

CAS Number

654671-77-9

Formula

C¹⁶H²⁰F⁶N⁵O⁶P

Molecular Weight

523.32

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

White or Off-white solid

Solubility(25℃)

DMSO

≥50mg/mL

Ethanol

Insoluble

Water

≥35mg/mL

l  Biological Information

Biochem/Physiol   Actions

Sitagliptin Phosphate is the phosphate salt form of sitagliptin, an orally available, competitive, beta amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis.

Application

1.    Dipeptidyl-Peptidase IV Inhibitors

Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.

2.    Hypoglycemic Agents

Substances which lower blood glucose levels.

3.    Incretins

Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.

l  Packaging & Storage

Packaging

250mg; 1g

Storage temp.

-20℃

l  Precautions and Disclaimer

This   product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov